BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cimino GD, Pan CX, Henderson PT. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis 2013;5:369-91. [PMID: 23394702 DOI: 10.4155/bio.12.325] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Ruddy KJ, Patel SR, Higgins AS, Armenian SH, Herrmann J. Cardiovascular Health during and after Cancer Therapy. Cancers (Basel) 2020;12:E3737. [PMID: 33322622 DOI: 10.3390/cancers12123737] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhu S, Zhu Z, Ma AH, Sonpavde GP, Cheng F, Pan CX. Preclinical Models for Bladder Cancer Research. Hematol Oncol Clin North Am 2021;35:613-32. [PMID: 33958154 DOI: 10.1016/j.hoc.2021.02.007] [Reference Citation Analysis]
3 Ni MW, Zhou J, Li H, Chen W, Mou HZ, Zheng ZG. Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry. Bioanalysis 2017;9:925-35. [PMID: 28617069 DOI: 10.4155/bio-2017-0031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. Chem Res Toxicol 2018;31:1042-51. [PMID: 30152692 DOI: 10.1021/acs.chemrestox.8b00107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Maatouk M, Abed B, Bouhlel I, Krifa M, Khlifi R, Ioannou I, Ghedira K, Ghedira LC. Heat treatment and protective potentials of luteolin-7-O-glucoside against cisplatin genotoxic and cytotoxic effects. Environ Sci Pollut Res Int 2020;27:13417-27. [PMID: 32026362 DOI: 10.1007/s11356-020-07900-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. J Cancer 2018;9:1455-65. [PMID: 29721056 DOI: 10.7150/jca.23356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rao D, Mallick AB, Augustine T, Daroqui C, Jiffry J, Merla A, Chaudhary I, Seetharam R, Sood A, Gajavelli S, Aparo S, Rajdev L, Kaubisch A, Chuy J, Negassa A, Mariadason JM, Maitra R, Goel S. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. Oncotarget 2019;10:5510-22. [PMID: 31565185 DOI: 10.18632/oncotarget.27140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Olelewe C, Kim JH, Ofori S, Mertens RT, Gukathasan S, Awuah SG. Gold(III)-P-chirogenic complex induces mitochondrial dysfunction in triple-negative breast cancer. iScience 2022;25:104340. [DOI: 10.1016/j.isci.2022.104340] [Reference Citation Analysis]
9 Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol 2018;31:1293-304. [PMID: 30381944 DOI: 10.1021/acs.chemrestox.8b00170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Wurz GT, DeGregorio MW. Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing. Int J Cancer 2015;136:1485-93. [PMID: 24510760 DOI: 10.1002/ijc.28773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Xin J, Wan Mahtar WNA, Siah PC, Miswan N, Khoo BY. Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti‑breast cancer agents. Mol Med Rep 2019;19:5368-76. [PMID: 31059050 DOI: 10.3892/mmr.2019.10201] [Reference Citation Analysis]
12 Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol 2016;29:1843-8. [PMID: 27657672 DOI: 10.1021/acs.chemrestox.6b00247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Göktürk T, Topkaya C, Sakallı Çetin E, Güp R. New trinuclear nickel(II) complexes as potential topoisomerase I/IIα inhibitors: in vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. Chem Pap . [DOI: 10.1007/s11696-021-02005-y] [Reference Citation Analysis]
14 Ay B, Şahin O, Saygıdeğer Demir B, Saygideger Y, López-de-luzuriaga JM, Mahmoudi G, Safin DA. Antitumor effects of novel nickel–hydrazone complexes in lung cancer cells. New J Chem 2020;44:9064-72. [DOI: 10.1039/d0nj00921k] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wills S, Hochmuth LK, Bauer KS Jr, Deshmukh R. Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma. Curr Probl Cancer 2019;43:181-94. [PMID: 30270097 DOI: 10.1016/j.currproblcancer.2018.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lu X, Li S, Chen W, Zheng D, Li Y, Li F. A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC. Medicine (Baltimore) 2020;99:e21170. [PMID: 32702875 DOI: 10.1097/MD.0000000000021170] [Reference Citation Analysis]
17 Rendošová M, Vargová Z, Kuchár J, Sabolová D, Levoča Š, Kudláčová J, Paulíková H, Hudecová D, Helebrandtová V, Almáši M, Vilková M, Dušek M, Bobáľová D. New silver complexes with bioactive glycine and nicotinamide molecules – Characterization, DNA binding, antimicrobial and anticancer evaluation. Journal of Inorganic Biochemistry 2017;168:1-12. [DOI: 10.1016/j.jinorgbio.2016.12.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
18 Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecol Oncol 2019;153:416-24. [PMID: 30797591 DOI: 10.1016/j.ygyno.2019.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
19 Chou HL, Fong Y, Wei CK, Tsai EM, Chen JY, Chang WT, Wu CY, Huang HW, Chiu CC. A Quinone-Containing Compound Enhances Camptothecin-Induced Apoptosis of Lung Cancer Through Modulating Endogenous ROS and ERK Signaling. Arch Immunol Ther Exp (Warsz). 2017;65:241-252. [PMID: 27677293 DOI: 10.1007/s00005-016-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Abdel-Fatah TMA, Ali R, Sadiq M, Moseley PM, Mesquita KA, Ball G, Green AR, Rakha EA, Chan SYT, Madhusudan S. ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers (Basel) 2019;11:E1149. [PMID: 31405143 DOI: 10.3390/cancers11081149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Saygıdeğer Demir B, Mahmoudi G, Sezan A, Derinöz E, Nas E, Saygideger Y, Zubkov FI, Zangrando E, Safin DA. Evaluation of the antitumor activity of a series of the pincer-type metallocomplexes produced from isonicotinohydrazide derivative. J Inorg Biochem 2021;223:111525. [PMID: 34237626 DOI: 10.1016/j.jinorgbio.2021.111525] [Reference Citation Analysis]
22 Papadaki C, Monastirioti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, Mavroudis D, Agelaki S. Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. Cancers (Basel) 2020;12:E1282. [PMID: 32438598 DOI: 10.3390/cancers12051282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One 2016;11:e0146256. [PMID: 26799320 DOI: 10.1371/journal.pone.0146256] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, Malfatti M, Haack K, Turteltaub KW, Pan CX, Cho M, Kim EJ, Henderson PT. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Mol Cancer Ther 2020;19:1070-9. [PMID: 32029633 DOI: 10.1158/1535-7163.MCT-19-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
25 Şanlı Ö, Lotan Y. Alternative therapies in patients with non-muscle invasive bladder cancer. Turk J Urol 2017;43:414-24. [PMID: 29201501 DOI: 10.5152/tud.2017.64624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
26 Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer 2017;141:604-13. [PMID: 28437852 DOI: 10.1002/ijc.30747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol 2017;30:388-409. [PMID: 27936622 DOI: 10.1021/acs.chemrestox.6b00380] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
28 Petrak K. Precision medicine and drug targeting. Nanostructures for the Engineering of Cells, Tissues and Organs. Elsevier; 2018. pp. 155-66. [DOI: 10.1016/b978-0-12-813665-2.00004-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Li Y, Deng H, Lv L, Zhang C, Qian L, Xiao J, Zhao W, Liu Q, Zhang D, Wang Y, Yan J, Zhang H, He Y, Zhu J. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget 2015;6:10195-206. [PMID: 25991669 DOI: 10.18632/oncotarget.3555] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
30 Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L, Xiao J, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y, Zhu J. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett 2015;357:105-13. [PMID: 25444900 DOI: 10.1016/j.canlet.2014.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
31 Cheff DM, Hall MD. A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research: Miniperspective. J Med Chem 2017;60:4517-32. [DOI: 10.1021/acs.jmedchem.6b01351] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 10.2] [Reference Citation Analysis]
32 Evans B, Iwayama T, Burnstock G. Long-lasting supersensitivity of the rat vas deferens to norepinephrine after chronic guanethidine administration. J Pharmacol Exp Ther. 1973;185:60-69. [PMID: 4693186 DOI: 10.3390/metabo5040571] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 1.8] [Reference Citation Analysis]
33 Behl T, Rachamalla M, Najda A, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Chigurupati S, Vargas-De-La-Cruz C, Hobani YH, Mohan S, Goyal A, Katyal T, Solarska E, Bungau S. Applications of Adductomics in Chemically Induced Adverse Outcomes and Major Emphasis on DNA Adductomics: A Pathbreaking Tool in Biomedical Research. Int J Mol Sci 2021;22:10141. [PMID: 34576304 DOI: 10.3390/ijms221810141] [Reference Citation Analysis]
34 Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther 2017;16:376-87. [PMID: 27903751 DOI: 10.1158/1535-7163.MCT-16-0381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
35 Enright HA, Malfatti MA, Zimmermann M, Ognibene T, Henderson P, Turteltaub KW. Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology. Chem Res Toxicol 2016;29:1976-86. [PMID: 27726383 DOI: 10.1021/acs.chemrestox.6b00234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 O'Hare A, Parks L. Bioanalysis annual round-up: the bioanalysis editorial team is delighted to welcome you to this mid-year round-up. Bioanalysis 2013;5:2227-31. [PMID: 24053237 DOI: 10.4155/bio.13.219] [Reference Citation Analysis]
37 Carper MB, Claudio PP. Clinical potential of gene mutations in lung cancer. Clin Transl Med 2015;4:33. [PMID: 26603430 DOI: 10.1186/s40169-015-0074-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
38 Cuello-nuñez S, Larios R, Deitrich C, Lekishvili T, Nischwitz V, Sharp BL, Goenaga-infante H. A species-specific double isotope dilution strategy for the accurate quantification of platinum–GG adducts in lung cells exposed to carboplatin. J Anal At Spectrom 2017;32:1320-30. [DOI: 10.1039/c7ja00078b] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Ritterson Lew C, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer. Nat Rev Urol 2015;12:383-91. [PMID: 26032551 DOI: 10.1038/nrurol.2015.111] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]